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Abstract
Background—The process of translating scientific findings into clinical and public health 
settings has only recently received priority attention within the scientific community.
Purpose—Fueled by “Funding Opportunity Announcements” from the National Institutes of 
Health and Centers for Disease Control and Prevention, scientists have begun to explore the 
pathways to effectively “transfer” promising research accomplishments into effective and 
sustainable service programs within the health care delivery system.
Method—Using Glasgow’s RE-AIM (Reach, Effectiveness, A-doption, Implementation and 
Maintenance) model as a guide, this research team enrolled 428 socially disadvantaged, culturally 
diverse women living with HIV/AIDS to test the dissemination and implementation of an 
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evidence-based behavioral intervention designed to improve and sustain the physical and 
emotional health of participants into the Community Health Center (CHC) setting when conducted 
by trained CHC staff.
Results—Findings demonstrate the ability of trained CHC staff group leaders to attain results 
equivalent or superior to those achieved when conducted by research staff on the three principal 
study outcomes: depression, medication adherence and HIV viral load. Four of five CHCs 
involved in the study also identified and successfully obtained funding to continue to run 
intervention groups, supporting the adoption and sustainability components of the translation 
model.
Conclusion—This study confirmed (a) the “translatability” of the Stress Management And 
Relaxation Training/Emotional Supportive Therapy (SMART/EST) Women’s Program, from 
academic to CHC settings in two geographic regions with high HIV prevalence among women, (b) 
the ability of local staff (using the “train the trainer” model) to successfully achieve program 
fidelity and clinical outcomes, and (c) the sustainability the program beyond the auspices of 
research support, through supportive CHC leadership securing continued program funding.
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Introduction
Over the past 30 years, health research has made extraordinary scientific progress in 
identifying efficacious strategies for disease prevention and control. However, the 
implementation of research findings into clinical and public health practice has not kept pace 
with “discovery,” due in part to the lack of scientific attention to the “translation” process 
itself. Translational research seeks to determine the most effective strategies to convert 
evidence-based scientific findings into practice, e.g., clinical services, community health 
care settings and public health programs [1].
Several publications from two studies conducted over the past 15 years by the University of 
Miami Miller School of Medicine (UMMSM) in Miami and Clinical Directors Network 
(CDN) in New York City, a primary care practice-based research network (PBRN), have 
confirmed the evidence base of the Stress Management And Relaxation Training/E-motional 
Supportive Therapy (SMART/EST) Women’s Program (SWP) [2–13]. SMART/EST was 
initially developed in 1996 by the UMMSM/CDN research team, and was subsequently 
tested and refined over the next 10 years in Florida, New York and New Jersey to serve the 
needs of women living with HIV/AIDS. Although the intervention was initially designed to 
enhance the overall quality of life and health status of culturally diverse, disadvantaged 
women living with AIDS, the advent of antiretroviral therapy (ART) transformed the 
prognosis for all persons living with HIV from preparing for imminent death to coping with 
a manageable chronic disease. It became apparent that women living with HIV/AIDS could 
expect to live relatively normal lives, albeit with challenging medication regimens and 
lifestyle changes necessary to preserve their vulnerable immune systems. Initial study 
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findings of improved health-related clinical outcomes among women with CDC-defined 
AIDS led to the expansion of the SMART/EST program to include all women living with 
HIV, adding a “healthy lifestyles” component (i.e., improved nutrition, exercise, medication 
adherence, reduced substance use) to also protect against other, non-HIV-related chronic 
diseases, e.g., cancer, cardiovascular disease, diabetes [14], and linguistically and culturally 
translating the entire program into Spanish and Haitian Creole [3].
This paper describes the process by which the SWP research team attempted to develop 
strong community–academic partnerships in order to convert scientific findings from this 
evidence-based intervention for women living with HIV into a viable, sustainable clinical 
service program for Community Health Centers (CHCs) and similar healthcare safety net 
practices, which could be conducted entirely by local staff, using the “train the trainer” 
dissemination and implementation research model. The principal study hypotheses 
compared the clinical outcomes achieved by the CHC staff with those achieved by the SWP 
research team, who were primarily Ph.D.-level clinical health psychologists. Guided by the 
REAIM conceptual model [15], CHC staff learned not only to conduct the program 
themselves, but also to teach others to become program leaders, thus providing one of the 
key links to program “sustainability,” following the termination of research study support 
(see Fig. 1).
This paper documents and compares the effectiveness of research and CHC staff to achieve 
comparable study outcomes (i.e., reduced depression, enhanced medication adherence and 
reduced HIV viral load). Findings related to enhancement of health behaviors have been 
detailed in a companion publication [16].
Methods
Prior to study onset, Institutional Review Board (IRB) approval was obtained from the 
University of Miami IRB and CDN IRB. All participants provided written informed consent 
in English, Spanish or Creole prior to enrollment.
Participants
Women living with HIV/AIDS (n=428) aged 18 years and older were enrolled in the study 
over a 2-year period. Active psychosis and severe depression were the only exclusion 
criteria. A small (n=64) “observation only” group was initially enrolled to assess “test–
retest” and secular trend factors during the course of the study period. Experimental group 
participants (n=364) were enrolled into Research-led (RES-led) and CHC staff-led (CHC-
led) groups following baseline assessment. Allocation of participants to RES-led and CHC-
led groups was not random, but rather, was carried out sequentially, with each site initially 
conducting research-led groups, followed by CHC-led groups. This approach was essential 
to the translation and training methodology, which provided CHC staff with the opportunity 
to learn to conduct the group intervention while at their job, without any loss of time at 
work. Participants from Miami (n=206) participated in RES-led (n=119) and CHC-led 
(n=87) groups. Participants from NY/NJ (n=158) participated in RES-led (n=77) and CHC-
led (n=81) groups.
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Participants were asked to complete a standardized assessment of medical, behavioral, and 
laboratory measures at baseline, 6 and 12 months post-baseline, conducted by a trained 
research assistant, using a notebook computer for electronic data capture [2]. As this study 
was carried out as a clinical service program, participants received no compensation for 
attending the 16 group psycho-educational sessions. However, participants did receive a 
modest cash honorarium consistent with IRB requirements for completing assessments. The 
following measures are of relevance to this paper (see the following subsections).
Depression—Scores on the Beck Depression Inventory-II (BDI) [17] of 14 or higher were 
considered to be “at risk” for the purposes of this study. The BDI is extensively used in 
psychological research and has demonstrated high reliability among both HIV-negative 
(alpha = 0.90) and -positive (alpha = 0.89–0.90) individuals in varied cultural settings [18–
20].
Medication Adherence—The AIDS Clinical Trials Group (ACTG) measure for 
Adherence to Anti-HIV Medications [21] assessed missed doses over the previous 2 weeks 
and 3 months. Adherence was dichotomized as having skipped medication within the 
previous 2 weeks or not. “At risk” participants were identified as endorsing non-adherence 
to medication within the previous 3 months from baseline.
HIV Viral Load—Viral load data were collected via medical chart abstraction at all sites. 
Values were log-transformed to stabilize the variance. Participants with a detectable viral 
load (>50 copies) at baseline were considered “at risk.”
Intervention
The SMART/EST Women’s Program (SWP) adapted a well-documented group behavioral 
intervention format known to reduce distress [22–24], improve health [25] and decrease risk 
behaviors [26–29] to the needs of ethnically diverse, disadvantaged women living with HIV/
AIDS. The group intervention consisted of 16 weekly, 2-h sessions, with the initial ten 
sessions focused on stress management to reduce depression, anxiety, and improve 
medication adherence and coping skills, followed by six sessions targeting nutrition, 
physical activity, sexual risk behavior, and alcohol, tobacco and drug use [16].
Sites and Staff
Five Health Resources and Services Administration (HRSA)-supported CHCs serving 
women living with HIV/AIDS in Miami, FL (two sites), and the New York metropolitan 
area (two NYC sites and two Northern NJ sites) participated in this study. Each site, in 
collaboration with UMMSM and CDN research teams, selected CHC staff to receive 
training in the SWP program. Following an initial 4-day intensive training workshop, 
UMMSM or CDN research staff were assigned to each CHC to lead the first two 
intervention groups, with doctoral level SWP research staff functioning as group leaders and 
CHC staff serving as co-leaders. After completion of two cohorts of 16 group sessions over 
a 4-month period, the SWP research and CHC staff members switched roles for the next two 
cohorts, with CHC staff serving as group leaders and the SWP research staff serving as co-
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leaders, providing oversight, clinical supervision and feedback to the CHC staff (the initial 
four cohorts were designated as RES-led for analytic purposes). The final four cohorts 
(CHC-led) involved only CHC staff as group leaders, also serving as trainers for additional 
CHC staff (group co-leaders), using the SWP intervention manual, training DVDs and 
leader session checklists, modeled on the training they received previously from the SWP 
research teams (see Fig. 1). Research staff maintained involvement throughout the CDC-
supported 3-year study period, conducting periodic quality assurance site visits and 
reviewing randomly selected session audiotapes with CHC staff. Implementation fidelity 
was assessed by the use of an “intervention content checklist” which was completed by the 
lead facilitator after each session. The checklists consisted of a list of all major topic areas 
covered in each session. Each topic covered in the session was assigned a completion score 
on a 3-point scale (0 = not addressed at all, 1 = addressed some components, 2 = addressed 
all components).
Translation
RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) was the 
theoretical model [15] used to assess clinical and organizational translational variables [3]. 
CHC health care providers with varied educational and experience backgrounds (counselors, 
social workers, health educators) were trained by SWP research staff to both conduct the 
program and to train others to become group leaders. As they progressed from “workshop 
participants” (initial orientation) to “group Co-leaders” (4–6 months) to “Group Leaders” 
(additional 4–6 months), they also became trainers of other CHC staff (see Fig. 1). This 
translational training strategy, which has been used in a variety of health care settings [30] 
created a “reservoir” of competent trainers and group leaders for their site, as well as a 
potential regional resource for other CHCs, thereby enhancing sustainability and further 
dissemination of the program.
Statistical Analyses
Two analyses were conducted for each primary outcome. An analysis was performed on the 
total sample, including all women receiving the SWP3 intervention. The full sample, 
however, included women who were not depressed, and/or were totally adherent to their 
HIV medications, and/or had undetectable HIV viral loads at study entry, suggesting the 
possibility of ceiling effects at baseline for some participants. Therefore, pre-specified 
subgroup analyses examined changes for those participants who were “at risk” for 
depression, non-adherence, or had detectable HIV viral loads at baseline.
Univariate analyses were utilized to describe the frequencies of demographic and outcome 
variables at baseline, and t-tests and chi-square tests of independence were performed to test 
differences between facilitator types and geographic sites. Longitudinal analyses included 
repeated measures logistic regression and ANOVA. A full factorial combination of time 
(T1, T2, T3), facilitator type (RES-led vs. CHC-led), and geography (NYC/NJ vs. Miami) 
was included as predictors (If non-significant, the three-way interaction was dropped from 
final models). F statistics and corresponding p-values for type III tests of time, facilitator 
type, and the interaction between time and facilitator type are presented. If a parameter was 
significant, appropriate pairwise comparisons were conducted. No adjustments were made 
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for multiple comparisons. All analyses were carried out with SAS PROC MIXED and 
PROC GLIMMIX (SAS 9.2, SAS Institute, Cary, NC, USA) using a two-tailed level of 
significance of α=0.05.
Results
Demographic and Baseline Characteristics
Participants were a mean age of 45±9 years and most were African-American (59 %) or 
Hispanic (23 %). The majority were unemployed (84 %) and considered disabled (61 %), 
reporting an annual income of less than $10,000 (85 %). Over half (57 %) had completed 
less than 12 years of education. Sixty-three percent were single and 86 % had children; 78 % 
reported sexual intercourse as the source of their HIV infection.
Several baseline characteristics differed between study sites. More participants in Miami 
reported disability status than NY/NJ (χ2=6.77, p<0.01). Participants in NY/NJ had 
significantly higher mean log Viral Loads (NY/NJ=2.8±1.3 vs. Miami=1.5±1.7, t=6.94, 
p<0.001) and significantly higher levels of depression at baseline than those in Miami (NY/
NJ=17.3±13.9 vs. Miami=12.9±12.0, t=3.20, p<0.01). NY/NJ participants were also more 
likely to report skipping medication in the last 2 weeks (55 %) as compared to Miami (39 %, 
χ2=6.83, p<0.01). To account for these differences, multivariate models adjusted for 
geographic site (Miami vs. NY/NJ). Table 1 presents comparisons of demographic and 
baseline outcomes by facilitator type. Overall, 278 of the 364 experimental condition 
participants (76 %) completed more than one assessment, and were available for analysis. 
Table 2 presents the sample size at each assessment timepoint by condition and site and the 
number available for analysis.
Depression, Medication Adherence and HIV Viral Load (DMV)
Observation-Only Group—Women without exposure to the SMART/EST intervention 
did not experience any reductions in depression, improvements in medication adherence, or 
declines in HIV viral load. There was an increase in mean log viral load from baseline to T2 
[mean (T2)=2.18 vs. m (T1)=2.16, t=2.10, p<0.05], but no change from T2 to T3.
Experimental Group
Depression — Full Sample—Among participants receiving the SMART/EST 
intervention, depression was examined over time. At baseline, participants reported 
moderate levels of depression (mean BDI=14.8± 13.0). Longitudinally, there was a 
reduction of depression over time [F(2,456)=13.69, p<0.001], but no effect of facilitator 
(F=0.49, p>0.05) or time by facilitator interaction (F= 1.32, p>0.05). Further examination of 
timepoints revealed that depression scores decreased significantly from baseline to T2 
[t(224)=−2.6, p<0.01] and the reduction was maintained at T3 [t(235)=3.73, p<0.01].
Depression — “At Risk” Subgroup—Among the “at risk” subgroup (those with 
baseline BDI ≥14), the reduction in depression was more pronounced. The decrease over 
time was significant [F(2, 160)=42.63, p<0.001], but there was no effect of facilitator 
(F=0.74, p>0.05) or interaction between time and facilitator (F=0.65, p>0.05). Comparisons 
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demonstrated decreases in depression from baseline to T2 [t(91)=−4.32, p<0.001] and 
baseline to T3 [t(100)=8.09, p<0.001]. Figure 2 displays changes in depression over time by 
facilitator type for both full sample and “at risk” participants.
Medication Adherence — Full Sample—At baseline, 63 % (n=170) of participants 
using ART (n=269) reported perfect adherence. Over time, there was no change in the odds 
of skipping medication in the past 2 weeks (F(2,297)=0.11, p>0.05). The effect of facilitator 
(F=0.77, p>0.05) and the interaction between time and facilitator were not significant 
(F=0.21, p>0.05).
Medication Adherence — “At Risk” Subgroup—Participants who reported any non-
adherence within the previous 3 months at baseline (n=99, 37 % of those using ART) were 
considered “at risk.” For these participants, the odds of skipping medication in the past 2 
weeks decreased over time (F(2,95)= 4.77, p<0.05). The odds of skipping medication within 
the past 2 weeks at baseline were 0.98, decreasing to 0.41 at T2 and 0.34 at T3. The decrease 
in odds was significant from T1 to T2 (t=2.26, p<0.05) and T1 to T3 (t=2.75, p<0.05), but 
the additional change observed from T2 to T3 was not significant (t=0.44, p>0.05). The 
increase in medication adherence did not differ between facilitator types (F=2.01, p>0.05) or 
over time by facilitator type (F=0.30, p>0.05). Figure 3 demonstrates change in medication 
adherence over time by facilitator type for both full sample and “at risk” participants.
Log Viral Load — Full Sample—Mean log viral load at baseline was 2.18±1.67. In the 
full sample, there was no change in log viral load over the course of the study [F(2, 
337)=1.04, p>0.05], no effect of facilitator (F=1.24, p>0.05) and no time by facilitator 
interaction (F=0.35, p>0.05).
Log Viral Load — “At Risk” Subgroup—Reductions in HIV log viral load over time 
were observed for participants who had a detectable viral load at baseline (n=130) [F(2, 
91)=21.69, p<0.001]. There was a main effect of facilitator (F=4.38, p<0.05), but no time by 
facilitator interaction (F=1.04, p>0.05). Further examination of viral load revealed 
significant decreases between baseline and T2 [t(52)= 3.96, p<0.01] and baseline and T3 
[t(71)=5.50, p<0.001]. Averaged over time, viral load was significantly lower in the CHC-
led group than the RES-led group [mean(CHC-led)= 3.31, mean(RES-led)=3.47, t=2.09, 
p<0.05] (see Fig. 4).
Process Measures: Implementation Fidelity
The fidelity assessment was completed for a sample of approximately 50 % of study 
sessions, and the mean completion score for all sessions was 1.74 (SD ± 0.13, range = 1.50–
1.94), suggesting a high level of fidelity to the curriculum. Among research-led groups, the 
mean completion score for all sessions was 1.68 (SD ± 0.22, range = 1.21–1.96), and among 
CHC-led groups, the mean completion score for all sessions was slightly higher at 1.81 (SD 
± 0.08, range = 1.65–1.93), suggesting comparable levels of fidelity were obtained by both 
research-led and CHC-led facilitators. Additional process measures include participant 
attendance, and these will be reported in detail in a subsequent paper examining moderators 
and mediators of implementation.
Weiss et al. Page 7














Baseline differences between geographic sites were noted for depression, medication 
adherence, and detectable viral load favoring the Miami site compared to NY/NJ. These 
findings contrast with our earlier studies which found more favorable baseline health 
profiles for NY/NJ compared to Miami. Although these differences may reflect idiosyncratic 
differences in the demographic populations served by the participating CHCs, it is also 
possible that these differences represent potential barometric shifts in uptake/adoption of 
more aggressive treatment policies in Miami over the 15-year span encompassed by these 
studies.
The longitudinal findings concerning the principal clinical outcomes (depression, 
medication adherence and log viral load) were comparable to the earlier SWP1 [11] and 
SWP2 [2] studies, suggesting that fidelity to protocol was maintained by both the Research-
led and CHC-led groups. Among the “Observation Only” participants, there was a 
significant increase in log viral load from baseline to T2, however, no other significant 
changes were observed. As expected, the improved clinical outcomes were most noticeable 
for the “at risk” participants, although a significant reduction in depression was also noted 
for all experimental participants, as well.
Of specific importance to the objectives of this study were the “translation of research into 
practice” results, which demonstrated equivalence of outcomes when comparing Research-
led vs. CHC-led groups. In those cases where differences between Research vs. CHC 
facilitators were noted, the outcome favored the CHC-led groups (e.g., larger decreases in 
depression and better adherence outcomes were observed in the “at risk” CHC-led groups, 
albeit not statistically significant). These trends may actually reflect the prior and continuing 
therapeutic relationships between CHC staff and their patients. Thus, the SWP translation 
model demonstrated that the intervention could be translated to the CHC setting and 
successfully implemented and conducted by trained CHC staff.
The process by which this behavioral intervention was evaluated for efficacy and 
effectiveness has been previously described [3]. Glasgow’s RE-AIM model [15] to 
determine whether the intervention could be successfully “translated” into clinical practice 
settings utilizes five components: Reach, Effectiveness, Adoption, Implementation and 
Maintenance.
• Reach represents the individuals’ willingness to participate in the program: of the 
eligible population of women offered the program, 60–80 % agreed to participate 
over the 2-year recruitment period.
• Effectiveness describes the impact of the intervention on desired outcomes: both 
RES-led and CHC-led groups achieved changes in study outcomes in SWP3, 
comparable with SWP1 and SWP2, particularly among those defined as “at risk.”
• Adoption concerns the representativeness of the CHCs that incorporated the 
intervention into their healthcare services delivery: four of the five CHCs 
successfully incorporated the intervention into their clinical services program for 
the duration of the research program.
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• Implementation describes fidelity to the elements of the intervention and 
consistency of delivery: the quality assurance and clinical supervision activities of 
the Research staff identified no significant departures from the protocol defined in 
the Intervention Manual. Importantly, the level of clinical effectiveness observed 
among CHC-led groups was comparable to the Research-led facilitators’ 
effectiveness. In all CHCs, numerous implementation challenges were raised 
during the course of the study that were negotiated from the perspective of 
systematically transferring decision-making to CHC staff; this suggests that local 
adaptation by CHC staff may have represented minor departures from fidelity 
which did not reduce overall program effectiveness (these will be reported in a 
qualitative paper on lessons learned during intervention implementation).
• Maintenance is the extent to which the program becomes part of the “standard of 
care” within the CHC and is sustained after support for the research component has 
been withdrawn: at present, four of the five CHCs have continued the program 
beyond the termination of the research component. Data on long term follow-up (1 
and 2 years post-study) will be collected and reported in the implementation paper 
concerning sustainability. The issues related to the fifth CHC began early in the 
translation process, with poor recruitment and retention, as well as lack of 
infrastructure support due to changes in senior leadership during the “start-up” 
phase of the program. These issues will be detailed in a subsequent paper related to 
organization-related issues of implementation and sustainability.
The RE-AIM model provided a comprehensive framework to gauge organizational as well 
as clinical success of the translational process. It was noted that program maintenance was 
dependent in large measure on the proactive identification of sources of revenue to sustain 
the program beyond its research and demonstration phases, such as Medicaid reimbursement 
and Ryan White funding. Such funding was instrumental in sustaining the program at four of 
the five participating CHCs. Medicaid reimbursement is related in large part to capitation, 
since most patients enrolled in Medicaid have their services reimbursed within a managed 
care model, rather than a fee-for-service model. Similarly, Ryan White funding is not 
disbursed as fee-for-service, but rather, provides the opportunity for sustainability through 
supporting designated full-time equivalent (FTE) behavioral staff who will be onsite and 
once trained, can continue to provide group behavioral services using the SWP intervention. 
Therefore, this model for translation needs to consider additional strategies for continued 
program support through existing health care reimbursement and grant-funded staffing 
structures.
Study Limitations
There were several limitations that should be kept in mind in evaluating study outcomes:
• The 3-year funding period limited follow-up to 1 year and precluded collecting 
long term clinical follow-up data (e.g., 2 years), as was the case in SWP2.
• The length of the intervention itself, as well as the extended training period, may be 
barriers to implementation in some settings; future studies could experiment with 
interventions of shorter duration (either fewer sessions and/or shorter duration of 
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each session), and with different types of staff with lesser education/training, as 
well as peer health educators.
• All fidelity assessments were self-assessments completed by the facilitators. 
External assessments by independent facilitators were limited to research staff 
randomly reviewing audiotaped sessions in order to provide quality assurance 
feedback to CHC staff.
• The study was conducted for the full study period at only four CHCs (two in Miami 
and two in NY/NJ) which may limit external validity, i.e., can these results be 
generalized to all CHCs in the US, or only those with a substantive census of HIV+ 
women, or those with a similar ethnic mix or those with similar structural/
organizational factors? Prior to considering a nationwide program, the next 
translational step should expand the regional coverage, e.g., offering the program to 
all CHCs in southern Florida and metropolitan New York/NJ with a patient census 
of women living with HIV.
• Cost-effectiveness analyses (CEAs) were not part of the initial analysis plans, and 
while financial data available from the research budget could be combined with 
effectiveness data to generate estimates of the cost-effectiveness ratio (CER), these 
would need to be interpreted with caution in the absence of a formal CEA. 
Furthermore, CHC adoption decisions are more likely to be based on the “business 
case” or Return-on-Investment (ROI) analyses, rather than CEA, so the 
implementation paper will examine ROI.
• Finally, this program has only been conducted with women. All four CHCs 
indicated interest in adapting the program to other HIV patient groups (e.g., men, 
pregnant women, transsexuals, couples), as well as non-HIV patient groups. The 
successful implementation of the SWP intervention by CHC staff raises the 
possibility of adapting the group behavioral intervention curricula to meet the needs 
of other patient populations and clinical conditions.
Conclusions
This translation pilot study demonstrated that a complex behavioral intervention, developed 
and refined under relatively controlled circumstances with highly qualified facilitators, could 
be successfully “translated” into the “real world” CHC health services environment and 
conducted by trained CHC staff without loss of fidelity or health benefits for participants. 
However, translating evidence-based interventions from academic research into the real 
world of service delivery is not for the “faint of heart”; developing support for the 
introduction of new services requiring extensive staff training requires patience, 
perseverance, and a willingness to negotiate with CHC leadership and staff on adapting the 
intervention to the CHC infrastructure. Transferring “ownership” without sacrificing “core” 
elements of the intervention in the health care infrastructure context required extensive and 
intensive interaction between researchers, CHC leadership and program facilitators. The 
centerpiece of the translation effort, the “training of trainers” model, provided the vehicle for 
the systematic succession from “outside experts” to on-site “indigenous” facilitators, capable 
of conducting the program, as well as training their CHC colleagues, a key element in 
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enabling new health care interventions and services to become self-sustaining, the final step 
in the RE-AIM model.
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Table 1







Age (years, mean) 45.4 44.8 0.64
Race/ethnicity 0.79
 Black/African-American 58.0 58.9
 Hispanic 24.1 22.0
 European 15.9 17.9
 Other 2.1 1.2
Born in US 82.1 85.7 0.89
Marital status 0.90
 Single/Never married 61.0 64.9
 Married 10.8 11.3
 Formerly married 28.2 23.8
Source of HIV infection 9.24*
 Sexual transmission 83.6 72.6
 Drug use 3.6 6.0
 Transfusion 3.1 1.8
 Don't know/other 9.7 19.6
Work status 0.07
 Not working 83.6 84.5
 Part-time/volunteer 12.8 11.9
 Full-time 3.6 3.6
On disability 62.1 59.3 0.29
Income 5.81
 Less than $5,000 34.4 46.4
 $5,100–$10,000 50.3 39.3
 More than $10,000 13.9 13.1
 Declined to answer 1.5 0.1
Education 4.98
 <High school 59.2 54.8
 High school 35.2 33.9
 1–2 years college 3.1 8.3






Mean BDI score 15.4 14.2 0.87
% moderately/severely
 depressed (BDI > 14)
49.0 40.5 2.64
% using ARV medication 81.0 74.4 2.3
% skipped medication within
 past 2 weeks
47.7 40.4 1.45




















Mean viral load (log transformed) 2.2 2.1 0.6
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Table 2
Loss to follow-up by site and condition among those with group assignment
Site
All participants Miami NY/NJ
Total RES-L CHC-L BQ JK BSa MH JC
Number assigned at baseline 364 196 168 111 95 0 62 96
T2 226 103 123 69 69 0 34 54
T3 237 125 112 65 68 0 37 67
N available for analysisb 278 (76 %) 152 (78 %) 126 (75 %) 78 77 NA 76 47
a
BS participants were not included in the analysis because of a high rate of drop out (approx. 70 %)
b
Completed more than one assessment
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